Article ID Journal Published Year Pages File Type
9872310 International Journal of Radiation Oncology*Biology*Physics 2005 8 Pages PDF
Abstract
Conclusions: Biologically potent doses of SBRT are well tolerated in patients with limited liver metastases. Results of this study form the basis for an ongoing Phase II SBRT study of 60 Gy over three fractions for liver metastases.
Keywords
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Preview
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases
Authors
, , , , , , , ,